Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Bruce J. Giantonio, Al B. Benson, Paul J. Catalano et al.|Journal of Clinical Oncology|2007Cited by 2.3k
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment OptionsLowell E. Schnipper, Richard L. Schilsky, Nancy E. Davidson et al.|Journal of Clinical Oncology|2015Cited by 903
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments ReceivedLowell E. Schnipper, Richard L. Schilsky, Dana S. Wollins et al.|Journal of Clinical Oncology|2016Cited by 654
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer CareNeal J. Meropol, Lowell E. Schnipper, Deborah Schrag et al.|Journal of Clinical Oncology|2009Cited by 635
High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200Bruce J. Giantonio, Al B. Benson, Paul J. Catalano et al.|Journal of Clinical Oncology|2005Cited by 344